Your Health, We Care
Avatrombopag is the world's first oral thrombopoietin receptor agonist (TPO-RA) approved by the US Food and Drug Administration (FDA) for the treatment of chronic liver disease (CLD) associated thrombocytopenia.
Patients treated with Avatrombopag have shown a significant increase in platelet count in clinical trials, reducing the occurrence of bleeding events. This improvement in efficacy is of great significance for improving patients' quality of life and prognosis.
